FDA Approves Merck ’s Keytruda (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
KENILWORTH, N.J.--(BUSINESS WIRE)--August 5, 2016 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab), the company ’s anti-PD-1...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Food and Drug Administration (FDA) | HNSCC | Merck | Skin Cancer | Squamous Cell Carcinoma